Arjumand S, Raj A, Prattay KMR, Omer HBM, Azam F. Chimeric antigen receptor T cell therapy: Revolutionizing cancer treatment. Volume 16. Baishideng Publishing Group Inc.; 2025. p. 108667. [cited 2026 Mar 23]. https://doi.org/10.5306/wjco.v16.i11.108667. World J Clin Oncol.

Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol Front Media S A. 2023;14:1188049. https://doi.org/10.3389/fimmu.2023.1188049.

Article  CAS  Google Scholar 

Escobar G, Berger TR, Maus MV. CAR-T cells in solid tumors: Challenges and breakthroughs. Cell Rep Med Cell Rep Med. 2025;6:102353. https://doi.org/10.1016/j.xcrm.2025.102353. [cited 2026 Feb 21];.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tu Z, Chen Y, Zhang Z, Meng W, Li L. Barriers and solutions for CAR-T therapy in solid tumors. Cancer Gene Therapy. 2025;32:9. Nature Publishing Group. 2025;32:923–34. https://doi.org/10.1038/s41417-025-00931-7.  Cited 21 Feb 2026.

Liu Z, Zhou Z, Dang Q, Xu H, Lv J, Li H, et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics Ivyspring Int Publisher. 2022;12:6273. https://doi.org/10.7150/THNO.76854. [cited 2026 Feb 21];.

Article  CAS  Google Scholar 

Khan TH, Muhammad N, Tarique M, Usmani D, Naz H, Sarode A, Media LLC. 2024;5:61–7. https://doi.org/10.1007/s43152-024-00055-4. Cited 23 Mar 2026.

Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Volume 8. Nature Publishing Group; 2023. pp. 9–. [cited 2026 Mar 23]. https://doi.org/10.1038/s41392-022-01270-x. Signal Transduction and Targeted Therapy 2022 8:1.

Huber F, Arnaud M, Stevenson BJ, Michaux J, Benedetti F, Thevenet J et al. A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy. Nat Biotechnol. 2024;43:8. Nature Publishing Group; 2024;43:1360–72. https://doi.org/10.1038/s41587-024-02420-y.  Cited 23 Mar 2026.

Le J, Dian Y, Zhao D, Guo Z, Luo Z, Chen X et al. Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment. Molecular Cancer 2025;24:1. BioMed Central; 2025;24:221-. https://doi.org/10.1186/s12943-025-02426-3. Cited 23 Mar 2026.

Wang S, Li X, Ning H, Wu Y. Dual-target CAR-T cell therapy: A new strategy to improve the therapeutic effect of hematological malignancies. Crit Rev Oncol Hematol. Elsevier; 2025;214:104824. https://doi.org/10.1016/j.critrevonc.2025.104824. Cited 23 Mar 2026.

Abbott RC, Cross RS, Jenkins MR. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies. Int J Mol Sci MDPI AG. 2020;21:515. https://doi.org/10.3390/IJMS21020515. [cited 2026 May 31];.

Article  CAS  Google Scholar 

Wang Y, Zhang B, Wang Y, Tan Y, Hu X, Che X, et al. T cell immunotherapy for solid tumors: limitations, progress, and future prospects. Front Immunol Front Media SA. 2026;17:1755751. https://doi.org/10.3389/FIMMU.2026.1755751. [cited 2026 May 31];.

Article  CAS  Google Scholar 

Zhang Z, Cui D, Wang H, Wu L, Liu X, Unleashing. CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy. Cancer Immunol Immunother. Springer Science and Business Media Deutschland GmbH; 2026;75:37. https://doi.org/10.1007/S00262-025-04278-8. Cited 31 Mar 2026.

Zhu J, Zhou J, Tang Y, Huang R, Lu C, Qian K, et al. Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions. Cancer Cell Int BioMed. 2025;25:313. https://doi.org/10.1186/s12935-025-03938-0. [cited 2026 Feb 23];. Central Ltd.

Article  CAS  Google Scholar 

Kembuan GJ, Kim JY, Maus MV, Jan M. Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology. Trends Cancer Elsevier. 2024;10:312–31. https://doi.org/10.1016/j.trecan.2024.01.003. [cited 2026 Mar 23];.

Article  CAS  Google Scholar 

Kundu S, Ray MD, Sharma A. Interplay between genome organization and epigenomic alterations of pericentromeric DNA in cancer. J Gen Genom. Elsevier; 2021;48:184–97. https://doi.org/10.1016/j.jgg.2021.02.004. Cited 23 Mar 2026.

Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat Commun Nat Res. 2023;14:5110. https://doi.org/10.1038/S41467-023-40850-5. [cited 2026 Jun 30];.

Article  CAS  Google Scholar 

Rezazadeh-Gavgani E, Majidazar R, Lotfinejad P, Kazemi T, Shamekh A. Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications. Immunity, Inflammation and Disease. John Wiley and Sons Inc; 2025;13:e70196. https://doi.org/10.1002/iid3.70196. Cited 23 Mar 2026.

Kuske M, Haist M, Jung T, Grabbe S, Bros M. Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses? Cancers (Basel). MDPI; 2022;14:1710. https://doi.org/10.3390/CANCERS14071710/S1. Cited 31 Mar 2026.

Biederstädt A, Rezvani K. Engineering the next generation of CAR-NK immunotherapies. Int J Hematol. Springer Japan; 2021;114:554. https://doi.org/10.1007/s12185-021-03209-4. Cited 23 Mar 2026.

Kundu S, Jit BP, Sharma A. Pan-cancer TCGA analysis reveals the potential involvement of B-type lamins in dysregulating chromosome segregation in human cancer. Mammalian Genome 2024 36:1. Springer; 2024;36:230–49. https://doi.org/10.1007/s00335-024-10086-9. Cited 23 Mar 2026.

Aleksander SA, Balhoff JP, Carbon S, Cherry JM, Ebert D, Feuermann M, et al. The Gene Ontology knowledgebase in 2026. Volume 54. Oxford University Press (OUP); 2025. p. D1779. [cited 2026 May 31]. https://doi.org/10.1093/NAR/GKAF1292. Nucleic Acids Res.

He W, Yuan K, He J, Wang C, Peng L, Han Y et al. Network and pathway-based analysis of genes associated with esophageal squamous cell carcinoma. Ann Transl Med. AME Publishing Company; 2023;11:102. https://doi.org/10.21037/ATM-22-6512. Cited 31 Mar 2026.

Bartha Á, Győrffy B, TNMplot. An enhanced platform for pharmacological target identification through cross-stage and pan-cancer gene expression analysis. Br J Pharmacol. John Wiley and Sons Inc; 2026. https://doi.org/10.1111/BPH.70390. Cited 22 Apr 2026.

Ono K, Fong D, Gao C, Churas C, Pillich R, Lenkiewicz J et al. Cytoscape Web: bringing network biology to the browser. Nucleic Acids Res. Oxford Academic; 2025;53:W203–12. https://doi.org/10.1093/NAR/GKAF365.  Cited 29 May 2026.

Bartha Á, Győrffy B, TNMplot. An enhanced platform for pharmacological target identification through cross-stage and pan-cancer gene expression analysis. Br J Pharmacol. John Wiley and Sons Inc; 2026;183:2648–59. https://doi.org/10.1111/BPH.70390. Cited 31 May 2026.

Yang A, Luo X, Guo Y, Zhang H, Zhang W, Chang S, et al. The network pharmacology prediction and experiment validation of Astragalus membranaceus for alleviating silicosis fibrosis via decreasing MMP9 and EGFR expression. Sci Rep Nat Res. 2026;16:12255. https://doi.org/10.1038/S41598-026-42544-6. [cited 2026 May 31];.

Article  CAS  Google Scholar 

Kumar S, Kundu S, Sharawat SK, Sharma A. Rewiring cancer epigenome: lncRNA as modulator of chromatin architecture and neoplastic transformation. Mammalian Genome. 2025;37:1. Springer; 2025;37:3-. https://doi.org/10.1007/s00335-025-10172-6. Cited 23 Mar 2026.

Burčík D, Macko J, Podrojková N, Demeterová J, Stano M, Oriňak A. Role of Cell Adhesion in Cancer Metastasis Formation: A Review. ACS Omega. American Chemical Society; 2025;10:5193. https://doi.org/10.1021/ACSOMEGA.4C08140. [cited 2026 May 31]

Burčík D, Macko J, Podrojková N, Demeterová J, Stano M, Oriňak A. Role of Cell Adhesion in Cancer Metastasis Formation: A Review. ACS Omega. Am Chem Soc. 2025;10:5193. https://doi.org/10.1021/acsomega.4c08140. [cited 2026 Mar 23].

Sanomachi T, Katsuya Y, Nakatsura T, Koyama T, Next-Generation CAR-T, Cell TCR-T. Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends. Cancers (Basel). Multidisciplinary Digital Publishing Institute (MDPI); 2025;17:1945. https://doi.org/10.3390/cancers17121945. [cited 2026 Mar 23].

Liang R, Liu L, Ding D, Li Y, Ren J, Wei B. CD155 promotes the progression of colorectal cancer by restraining CD8 + T cells via the PI3K/AKT/NF-κB pathway. Cancer Immunology. Volume 74. Springer; 2025. pp. 94–. [cited 2026 May 31]. https://doi.org/10.1007/S00262-025-03947-Y. Immunotherapy 2025 74:3.

Qian D, Guo J, Duan Y, Zhou Y, Wu C, Chen Q et al. Immunotherapeutic strategies targeting the PVR–TIGIT/CD96/CD226 signaling pathway in glioma treatment. Ann Med. Taylor and Francis Ltd. 2025;57:2588717. https://doi.org/10.1080/07853890.2025.2588717. [cited 2026 May 31].

Liu K, Liu Y, Xiong H, Ning Z. The Immune Regulatory Functions of CD226 and Its Implications in Immune-Mediated Diseases. Biomolecules. Multidisciplinary Digital Publishing Institute (MDPI). 2025;15:1007. https://doi.org/10.3390/BIOM15071007..

Xiong T, Wang G, Yu P, Li Z, Li D, Zhang J, et al. CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors. J Clin Invest Am Soc Clin Invest. 2025;135:e189920. https://doi.org/10.1172/JCI189920. [cited 2026 May 31].

Article  CAS  Google Scholar 

Gao J, Zheng Q, Xin N, Wang W, Zhao C. CD155, an onco-immunologic molecule in human tumors. Cancer Sci. Blackwell Publishing Ltd; 2017;108:1934. https://doi.org/10.1111/cas.13324. [cited 2026 Mar 23].

Pan C, Zhai Y, Wang C, Liao Z, Di Wang, Yu M et al. Poliovirus receptor–based chimeric antigen receptor T cells combined with NK-92 cells exert potent activity against glioblastoma. JNCI Journal of the National Cancer Institute. Oxford University Press; 2023;116:389. https://doi.org/10.1093/jnci/djad226. [cited 2026 Mar 23].

Liu X, Sun Y, Lin B, Xiong H, Lu X, Tan B, et al. Pan-cancer analysis identifies CD155 as a promising target for CAR-T cell therapy. Genome Med Genome Med. 2025. https://doi.org/10.1186/S13073-025-01490-0. [cited 2026 Feb 21];17.

Article  PubMed  PubMed Central  Google Scholar 

Zhang K, Mi Y, Zhang B, Xue X, Ding Y, Ma J, et al. Preclinical application of a CD155 targeting chimeric antigen receptor T cell therapy for digestive system cancers. Volume 44. Nature Publishing Group; 2025. pp. 1463–74. [cited 2026 Mar 23]. https://doi.org/10.1038/s41388-025-03322-2. Oncogene 2025 44:20.

Qiu Z, Wang Y, Zhang Z, Qin R, Peng Y, Tang W, et al. Roles of intercellular cell adhesion molecule-1 (ICAM-1) in colorectal cancer: expression, functions, prognosis, tumorigenesis, polymorphisms and therapeutic implications. Front Oncol Front Media S A. 2022;12:1052672. https://doi.org/10.3389/FONC.2022.1052672. [cited 2026 May 31];.

Article  CAS  Google Scholar 

Kang JH, Uddin N, Kim S, Zhao Y, Yoo KC, Kim MJ et al. Tumor-intrinsic role of ICAM-1 in driving metastatic progression of triple-negative breast cancer through direct interaction with EGFR. Mol Cancer. 2024;23:1. BioMed Central; 2024;23:230–. https://doi.org/10.1186/S12943-024-02150-4. [cited 2026 May 31].

Wei H, Wang Z, Kuang Y, Wu Z, Zhao S, Zhang Z et al. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer. Front Immunol. Frontiers Media S.A. 2020;11:573823–573823. https://doi.org/10.3389/fimmu.2020.573823. [cited 2026 Mar 23].

CAS  Google Scholar 

Yang Y, Sanders AJ, Ruge F, Dong X, Cui Y, Dou QP et al. Activated leukocyte cell adhesion molecule (ALCAM)/CD166 in pancreatic cancer, a pivotal link to clinical outcome and vascular embolism. Am J Cancer Res. 2021;11:5917. https://pmc.ncbi.nlm.nih.gov/articles/PMC8727815/. Accessed 31 May 2026.  [cited 2026 May 31].

Wang Y, Yu W, Zhu J, Wang J, Xia K, Liang C et al Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. Journal of Experimental & Clinical Cancer Research. Volume 38. BioMed Central Ltd.; 2019. p. 168. https://doi.org/10.1186/s13046-019-1147-6. [cited 2026 Mar 27].

He S, Li S, Guo J, Zeng X, Liang D, Zhu Y et al. CD166-specific CAR-T cells potently target colorectal cancer cells. Transl Oncol. Volume 27. Neoplasia Press, Inc.; 2022. p. 101575. https://doi.org/10.1016/j.tranon.2022.101575. [cited 2026 Mar 27].

Ji W, Zhuang X, Jiang WG, Martin TA. Tight junctional protein family, Claudins in cancer and cancer metastasis. Front Oncol Front Media SA. 2025;15:1596460. https://doi.org/10.3389/FONC.2025.1596460. [cited 2026 May 31];.

Article  CAS  Google Scholar 

Ji W, Zhuang X, Jiang WG, Martin TA. Tight junctional protein family, Claudins in cancer and cancer metastasis. Front Oncol Front Media SA. 2025;15:1596460. https://doi.org/10.3389/FONC.2025.1596460/FULL.

Article  CAS  Google Scholar 

Lee HJ, Hwang SJ, Jeong EH, Chang MH, Genetically Engineered. CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector. Journal of Microbiology. 2024;62:7. Springer; 2024;62:555–68. https://doi.org/10.1007/S12275-024-00133-0

Barrett AM, Britton ZT, Carrasco RA, Breen S, Broggi MAS, Hatke AL, et al. Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers. Clin Cancer Res Clin Cancer Res. 2024;30:5413–29. https://doi.org/10.1158/1078-0432.CCR-24-1853. [cited 2026 Feb 21];.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Birtel M, Voss RH, Reinhard K, Rengstl B, Ouchan Y, Michel K, et al. A TCR-like CAR Promotes Sensitive Antigen Recognition and Controlled T-cell Expansion Upon mRNA Vaccination. Cancer research communications. Cancer Res Commun. 2022;2:827–41. https://doi.org/10.1158/2767-9764.CRC-21-0154. [cited 2026 Feb 21];.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Madsen PJ, Schlitter AM, Flemmig C, Dickson C, Harvey K, Wilson C, et al. Claudin 6 is a suitable target for CAR T-cell therapy in atypical teratoid/rhabdoid brain tumors and other pediatric solid tumors. J Immunother Cancer J Immunother Cancer. 2025. https://doi.org/10.1136/JITC-2025-011709. [cited 2026 Jan 3];13.

Article  PubMed  PubMed Central  Google Scholar 

Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10:727. https://pmc.ncbi.nlm.nih.gov/articles/PMC7136921/. Accessed 21 Feb 2026. [cited 2026 Feb 21].

Li D, English H, Hong J, Liang T, Merlino G, Day CP et al. A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer. Mol Ther Oncolytics. Cell Press; 2022;24:849–63. https://doi.org/10.1016/j.omto.2022.02.015. [cited 2026 Jan 9].

Zhou JT, Liu JH, Song TT, Ma B, Amidula N, Bai C, EGLIF-CAR-T Cells Secreting. PD-1 Blocking Antibodies Significantly Mediate the Elimination of Gastric Cancer. Cancer Manag Res. Volume 12. Dove Medical Press Ltd; 2020. p. 8893. https://doi.org/10.2147/CMAR.S260915. [cited 2026 Mar 23].

Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFV by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol Nat. 2018;36:847–58. https://doi.org/10.1038/NBT.4195;TECHMETA. [cited 2026 Feb 21];. Publishing Group.

Article  CAS